Literature DB >> 6965328

Mouse leukemia: therapy with monoclonal antibodies against a thymus differentiation antigen.

I D Bernstein, M R Tam, R C Nowinski.   

Abstract

Monoclonal antibodies against a thymus cell differentiation antigen (Thy-1.1) were effective in the therapy of a transplanted mouse leukemia. Passive immunization resulted in high titers of cytotoxic antibody in the serum of treated mice and the suppression of metastatic tumor cells. The tumor-suppressive effects of the monoclonal antibodies were amplified by the administration of exogenous complement. This combined antibody and complement therapy resulted in the cure of leukemia in a significant proportion of the treated animals.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6965328     DOI： 10.1126/science.6965328

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  31 in total

1.  Thy-1 as a potential novel diagnostic marker for gastrointestinal stromal tumors.

Authors:  Despoina Oikonomou; Kambiz Hassan; Jussuf T Kaifi; Henning C Fiegel; Paulus G Schurr; Uta Reichelt; Kuniaki Aridome; Emre F Yekebas; Oliver Mann; Dietrich Kluth; Tim Strate; Jakob R Izbicki
Journal:  J Cancer Res Clin Oncol       Date:  2007-05-30       Impact factor: 4.553

2.  Factors influencing antibody-mediated cytotoxicity during the immunotherapy of Rauscher-virus-induced myeloid leukemic cells.

Authors:  D Berends; T H van der Kwast; N J de Both; P G Mulder
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Thymocytes expressing CD8 differentiate into CD4+ cells following intrathymic injection.

Authors:  J Nikolić-Zugić; M J Bevan
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

Review 4.  Human tumor-associated antigens identified by monoclonal antibodies.

Authors:  K E Hellström; I Hellström; J P Brown
Journal:  Springer Semin Immunopathol       Date:  1982

5.  Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity.

Authors:  U D Staerz; M J Bevan
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

6.  Rituximab for non-Hodgkin's lymphoma: a story of rapid success in translation.

Authors:  Andrew M Harrison; Nassir M Thalji; Alexandra J Greenberg; Carmen J Tapia; Anthony J Windebank
Journal:  Clin Transl Sci       Date:  2013-10-03       Impact factor: 4.689

7.  Monoclonal antibodies reactive with human myeloid leukaemia cells.

Authors:  E D Ball; M W Fanger
Journal:  Clin Exp Immunol       Date:  1982-06       Impact factor: 4.330

8.  Development of orally active inhibitors of protein and cellular fucosylation.

Authors:  Nicole M Okeley; Stephen C Alley; Martha E Anderson; Tamar E Boursalian; Patrick J Burke; Kim M Emmerton; Scott C Jeffrey; Kerry Klussman; Che-Leung Law; Django Sussman; Brian E Toki; Lori Westendorf; Weiping Zeng; Xinqun Zhang; Dennis R Benjamin; Peter D Senter
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-14       Impact factor: 11.205

9.  IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells.

Authors:  D Herlyn; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1982-08       Impact factor: 11.205

10.  Experimental tumoricidal effects of monoclonal antibody against solid breast tumors.

Authors:  P M Capone; L D Papsidero; G A Croghan; T M Chu
Journal:  Proc Natl Acad Sci U S A       Date:  1983-12       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.